Loss of Heterozygosity at the BRCA1 and BRCA2 Loci Detected in Ductal Lavage Fluid from BRCA Gene Mutation Carriers and Controls

  1. Imogen Locke1,2,
  2. Zsofia Kote-Jarai1,2,
  3. Elizabeth Bancroft1,2,
  4. Sarah Bullock1,
  5. Sarah Jugurnauth1,
  6. Peter Osin1,2,
  7. Ashutosh Nerurkar2,
  8. Louise Izatt3,
  9. Gabriella Pichert3,
  10. Gerald P. H. Gui1,2 and
  11. Rosalind A. Eeles1,2
  1. 1The Institute of Cancer Research; 2The Royal Marsden NHS Foundation Trust; and 3Guy's and St. Thomas' NHS Foundation Trust, London, United Kingdom
  1. Requests for reprints:
    Imogen Locke, Department of Cancer Genetics, The Royal Marsden NHS Foundation Trust, Orchard House, Downs Road, Sutton, Surrey SM2 5PT, United Kingdom. Phone: 44-20-8661-3105; Fax: 44-20-8770-1489. E-mail: imogen.locke{at}icr.ac.uk

Abstract

Female BRCA gene mutation carriers are at increased risk for developing breast cancer. Ductal lavage is a novel method for sampling breast ductal fluid, providing epithelial cells for cytologic assessment and a source of free DNA for molecular analyses. Loss of heterozygosity (LOH) at the BRCA loci in ductal lavage fluid is a potential biomarker of breast cancer risk. The LOH rate was measured at the BRCA1/2 loci and compared with that at a control locus (APC) using free DNA from the ductal lavage fluid of BRCA carriers and predictive test negative controls. We evaluated the reproducibility of these analyses. Free DNA sufficient for PCR amplification was obtained from 33 ductal lavage samples of 17 healthy women of known BRCA status (14 BRCA carriers and 3 controls). LOH rates of 36.4% to 56.3% at the BRCA1 locus and 45% to 61.5% at the BRCA2 locus were found among BRCA carriers. The LOH rate at the APC locus was lower (18.5%). The interaliquot reproducibility for the D17S855 marker of the BRCA1 locus was 66.7%. Intraaliquot reproducibility was 90%. Although we successfully isolated sufficient free DNA from ductal lavage fluid for PCR amplification, the degree of reproducibility of these LOH studies raises questions about the robustness of this technique as a risk assessment tool in the evaluation of high-risk women. Further studies are required to evaluate the specificity and predictive value of LOH in ductal lavage fluid for breast cancer development. (Cancer Epidemiol Biomarkers Prev 2006;15(7):1399–402)

Footnotes

  • Grant support: Cancer Research UK. Z. Kote-Jarai was funded by the legacy of the late Marion Silcock and is now funded by Breast Cancer Campaign. Prostate Cancer Research Foundation (S. Bullock).

  • The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

    • Accepted May 2, 2006.
    • Received December 26, 2005.
    • Revision received February 27, 2006.
« Previous | Next Article »Table of Contents